The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly-owned subsidiary and Daiichi Sankyo
Sun Pharmaceutical Industries including its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries has launched in US, the Authorized Generic (AG) version for Daiichi Sankyo’s Welchol (colesevelam hydrochloride) 625mg tablets.
The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly-owned subsidiary and Daiichi Sankyo, which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period. Welchol tablets recorded US sales of approximately $520 million for the 12 months ending March 2018, as per IQVIA.
Comments are closed.